BLOODPAC Quarterly Newsletter: Q1-Q2 2024
First half of 2024 News
Q1 In-person Meeting
Our invite-only Q1 meeting was generously hosted by Illumina in San Diego, CA. Attendees met in working group sessions on day 1 and presented updates, accomplishments, and next steps on day 2 in our all-members meeting.
Early Detection AACR Session
On April 6, 2024, at the AACR Annual Meeting, BLOODPAC hosted a special session on "Rethinking Risk and Risk Assessment for Liquid Biopsy-Based Single- and Multi-Cancer Screening." Panelists from Natera, GRAIL, the NCI, Guardant, Friends of Cancer Research, and Dana Farber discussed how the field is currently conceptualizing cancer risk in the setting of cancer screening guidelines, and whether we need to shift our thinking and terminology with the introduction of new single and multi-cancer early detection technologies. You can read the abstract here and a recap of the session here.
CHIP White Paper
If you missed our New Frontiers seminar on clonal hematopoiesis of indeterminate potential (CHIP) in December, a recording of the event and a white paper are available here! The seminar featured leading experts presenting their work on CHIP, covering topics from novel classification methods to CHIP as a risk factor for cardiovascular disease and heme malignancies.
Reimbursement & Policy Working Group Paper. BLOODPAC's Reimbursement & Policy working group just released a new white paper! Read here about how the group has accelerated the access, adoption and clinical implementation of blood-based testing and their call to action to payers and risk holders.
Risk Holder Engagement Working Group White Paper. BLOODPAC's Risk Holder Engagement Working Group has published a new white paper! This publication emphasizes the need for payer engagement in ensuring patient access to liquid biopsy in cancer care. Read more about why the payer's voice is needed here.
JCO PO Podcast. Earlier this year, our Executive Director, Lauren C. Leiman, and Dr. Emma B. Alme from Guardant Health joined Dr. Rafeh Naqash on the JCO Precision Oncology Conversations podcast to discuss the transformative impact of liquid biopsies in cancer care. Listen to the podcast here.
New Working Group! Following the success of our New Frontiers seminar last year, we are excited to announce the establishment of our newest working group. The CHIP Working Group aims to address gaps in CHIP terminology, standardize evaluation of CHIP detection techniques, and to recommend concepts guiding the utility of this biomarker in clinical and translational applications. The group discussions will be led by Bob Tell from Tempus, Larry LaPointe from Quest Dx, and Ahmet Zehir from Natera.
BLOODPAC welcomes new members!
Tasso is a Seattle-based startup developing at-home blood collection kits for both liquid blood and dried blood spots.
The International Society of Liquid Biopsy (ISLB) founded in 2017 in Granada, Spain, ISLB brings together healthcare professionals, primarily oncologists, who have adopted liquid biopsies as a new clinical tool.
Tecan a Swiss company that supports customers in healthcare and life sciences from early-stage innovation to project implementation and beyond.
New team members! We are thrilled to welcome our newest team members Cheyenne Jankiewicz and Dorys Lopez.
Cheyenne joins us as our new Program Manager and Data Coordinator.
Dorys joins us as our new Head of Scientific Communications.
We are excited to have Cheyenne and Dorys on board and look forward to their contributions to our team.
Upcoming Events
BLOODPAC Q3 MEETING September 4th and 5th, 2024: BLOODPAC’s Q3 meeting will be hosted by Personalis in Freemont, CA. Invitations and details were emailed early in June. If you did not receive the information, please send us an email at info@bloodpac.org.
